Hematology

February 13th 2025

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.

February 12th 2025

Interim data from the ECHELON-3 trial previously showed that adding brentuximab vedotin to lenalidomide and rituximab improved overall survival among patients who have relapsed or refractory large B-cell lymphoma (R/R LBCL).

February 10th 2025

Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, highlighting disparities in specialized cancer care.

February 7th 2025

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, hurdles that include availability and cost remain to its widespread implementation.